Xeris Biopharma Holdings, Inc. SEC filings XERS
Xeris Biopharma Holdings, Inc. has 345 filings in SEC EDGAR's recent list, going back to Jul 2, 2021. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Mar 2, 2026 | — |
| S-8 | Employee stock plan registration | Mar 6, 2025 | — |
| S-3 | Shelf registration | Mar 6, 2025 | — |
| S-8 | Employee stock plan registration | Aug 8, 2024 | — |
| S-8 | Employee stock plan registration | Mar 6, 2024 | — |
| S-8 | Employee stock plan registration | Mar 8, 2023 | — |
| 424B5 | Prospectus supplement | May 11, 2022 | — |
| S-8 | Employee stock plan registration | Mar 11, 2022 | — |
| 424B3 | Prospectus | Feb 8, 2022 | — |
| S-3 | Shelf registration | Jan 28, 2022 | — |
| S-3 | Shelf registration | Jan 28, 2022 | — |
| S-8 | Employee stock plan registration | Oct 5, 2021 | — |
| 424B3 | Prospectus | Jul 29, 2021 | — |
| S-4/A | Filing | Jul 28, 2021 | — |
| S-4 | Registration for a merger or exchange | Jul 2, 2021 | — |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XERS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Chicago, IL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1867096
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.